| Table 2. Summary of S | Studies Assessir | ig the Association Betwee | n Depression and Diabetes Inciden | | |
|--|-----------------------------------|---|--|--|--|
| | _ | | Impact of Depression on Comorbidity ^a | | |
| Study (N), Design | Depression Definition | Estimate; Time Period | Presence of Depression | Depression Recurrence/ Severity ^b | |
| Diabetes Only | DEEV | | | ND | |
| Atasoy et al 2018 ³¹ (MONICA/ KORA) | DEEX score≥10/12, | HR (95% CI) for developing T2DM; mean 15.4-year | Overall: 1.16 (1.06 to 1.02); <i>P</i> =.02 Normal weight, depressed: 1.30 (0.90 | NR | |
| (N=9,340) | men/women | follow-up ^c | to 1.91) | | |
| Prospective cohort | | | Overweight: 3.11 (2.30 to 4.21); P<.0001 Obese: 8.05 (5.90 to 10.98); P<.0001 | | |
| Brown et al 2005 ³² | ICD codes | OR (95% CI) history of | Overall: 1.47 (1.14 to 1.90); P=.002 | NR | |
| (N = 9,340) Retrospective case- control | | depression and incident T2DM; 3-year exposure period ^d | Age 20–50 years: 1.23 (1.10 to 1.37) Age ≥ 51 years: 0.92 (0.84 to 1.00) | | |
| Campayo et al 2010 ³³ | GMS-AGECAT | HR (95% CI) depression as | Overall: 1.65 (1.02 to 2.66); P=.04 | Nonsevere: 1.66 (1.01 to 2.75); | |
| (ZARADEMP) (N = 3,521) | (details NR) | predictor of diabetes; 5-year follow-up ^e | First episode: 1.59 (0.96 to 2.64); <i>P</i> = .07 Baseline only: 1.43 (0.79 to 2.58); <i>P</i> = .24 | P=.048 Severe: 1.57 (0.55 to 4.44); | |
| Prospective cohort | | lollow-up | Untreated: 1.83 (1.11 to 2.99); <i>P</i> = .02 | P=.39 | |
| | | | Treated: 0.823 (0.23 to 2.98); <i>P</i> = .77 | Previous episode: 2.06 (0.73 to 5.70); $P = 17$ | |
| | | | | 5.79); P = .17 Baseline + follow-up: 2.09 (1.0 to 4.14); P = .03 | |
| Eriksson et al 2008 ³⁴ | Patient | OR (95% CI) depression | NR | Men Middle on Low 1.2 (1.0 to 1.7) | |
| (Stockholm Diabetes Prevention Program) | questionnaire | quartile at baseline (low, middle, and high) and T2DM | | Middle vs low: 1.3 (1.0 to 1.7) High vs low: 1.6 (0.6 to 4.3) | |
| N=5,227) | | at 8- to 10-year follow-up ^f | | Women | |
| Prospective cohort | | | | Middle vs low: 1.0 (0.7 to 1.3) High vs low: 0.7 (0.3 to 1.6) | |
| armer et al 2008 ³⁵ | DSM-IV or ICD | OR (95% CI) for T2DM | NR | 2.06 (0.84 to 5.04); P = NS | |
| N=2,430) | recurrent MDD | in cases with recurrent | | | |
| Retrospective case- control | criteria using SCAN 2.1 | depression vs controls; lifetime history assessed ^g | | | |
| Karakus and Patton | 8-item | OR (95% CI) depression at | Overall: 1.50 (1.01 to 2.24); P=.04 | NR | |
| 2011 ³⁶ (Health and Retirement Study) | CES-D score \geq 3 | baseline as predictor of diabetes; 12-year follow-up ^h | Including excessive alcohol drinking: 1.505; P = .044 | | |
| N=3,645) | | diabetes, 12 year follow up | 1.505,7044 | | |
| Prospective cohort Kivimäki et al 2010 ³⁷ | ICD codes | Study 1, OD (05% CI) for | | (autores 1.42/1.01 to 1.00) | |
| N = 59,940 | ICD codes | Study 1: OR (95% Cl) for incident T2DM, depression | Untreated: 1.05 (0.55 to 2.04) Antidepressant use: 2.76 (1.93 to 3.94) | Severe: 1.42 (1.01 to 1.99) | |
| Retrospective case- | | vs no depression; 4-year | | | |
| control | | follow-up ⁱ Study 2: HR (95% Cl) for | 200–399 defined daily doses/year: 1.53 | NR | |
| | | incident T2DM associated | (1.25 to 1.87) | INIX | |
| | | with antidepressant use; mean 4.75-year follow-up ⁱ | ≥400 defined daily doses/year: 2.00 (1.51 to 2.66) | | |
| | | mean 4.75-year tonow-up | <i>P</i> trend < .0001 | | |
| Vallon et al 2005 ³⁸ | Self-report | RR (95% CI) new diabetes | Women: 1.0 (0.3 to 3.2)/0.9 (0.3 to 2.9) | NR | |
| N = 1,187) Prospective cohort | | according to depression at baseline; 12-year follow-up ^j | Men: 0.6 (0.2 to 2.0)/1.3 (0.4 to 3.6) ^k | | |
| Mezuk et al 2008a ²⁸ | DIS; details NR | HR (95% CI) risk of T2DM | 1981–2005: 1.62 (1.03 to 2.55); P < .05 | NR | |
| Baltimore ECA) N = 3,481) | | according to lifetime MDD; 24-year follow-up ^l | 1993–2005: 2.04 (1.09 to 3.81); <i>P</i> < .05 | | |
| Prospective cohort | | | | | |
| Mezuk et al 2015 ³⁹ (SALT) | DSM-IV MDD | HR (95% CI) lifetime MDD | Overall: 1.07 (0.91 to 1.26) | NR | |
| N = 37,043) Cross-sectional | using CIDI-SF | predicting T2DM; 4-year follow-up ^m | <u>Age 40–55 years</u> All: 1.32 (1.00 to 1.80) | | |
| | | | Women: 1.74 (1.09 to 2.79) | | |
| | | | Men: 1.08 (0.70 to 1.67) <u>Age > 55 years</u> | | |
| | | | All: 1.00 (0.83 to 1.21) | | |
| | | | Women: 0.92 (0.72 to 1.18) Men: 1.17 (0.87 to 1.57) | | |
| Nichols and Moler 2011 ⁴⁰ | ICD codes | RR (95% CI) risk of T2DM | 1.10 (1.02 to 1.20) | NR | |
| (N = 58,056) Retrospective cohort | | according to depression; follow-up≤5 years ⁿ | | | |
| Pan et al 2010 ⁴¹ (Nurses' | Self-report; | RR (95% CI) incident T2DM | Any depressed mood: 1.17 (1.05 to | By MHI-5 score | |
| Health Study) | MHI-5 score ≤ 52 | according to depressive | 1.30) | 86–100: reference | |
| (N=65,381) Prospective cohort | or with clinical depression | symptom status; 10-year follow-up° | Physician-diagnosed, untreated: 1.05 (0.85 to 1.30) | 76–85: 1.07 (0.97 to 1.17) 53–75: 1.13 (1.02 to 1.26); | |
| | 300.00000 | | Physician-diagnosed, with | <i>P</i> trend = .002 | |
| Windle and Windle 2013 ⁴² | DSM-IV MDD | OR (95% Cl) lifetime MDD | antidepressants: 1.25 (1.10 to 1.41) Single MDD: 0.5 (0.13 to 1.88) | ≤ 52: 1.04 (0.83 to 1.31) Recurrent MDD: 3.20 (1.10 to | |
| (N = 557) | criteria using | predicting T2DM; 5-year | ט ניואס (0.10 ניו 1.00) איז | 9.33); P<.05 | |
| Prospective cohort | CIDI | follow-up ^p | | | |
| Diabetes as a Component o Block et al 2016 ⁴³ (SHIP-0; | of Metabolic Syndro DSM-IV MDD | ome OR (95% Cl) MDD and | Women | Recurrent MDD | |
| SHIP-TREND-0) | criteria using | elevated glucose or | SHIP-0: 1.49 (0.92 to 2.41) | Women: 0.73 (0.47 to 1.12) | |
| (N=8,040) | CID-S or M-CIDI | antidiabetic medication; | SHIP-TREND-0: 0.96 (0.70 to 1.32) | Men: 1.25 (0.81 to 1.93) | |
| Cross-sectional | | 4-year follow-up ^q | MDD lifetime: 0.85 (0.58 to 1.23) <u>Men</u> | | |
| | | | SHIP-0: 0.94 (0.50 to 1.78) | | |
| | | | SHIP-TREND-0: 1.21 (0.89 to 1.65) MDD lifetime: 1.23 (0.87 to 1.75) | | |
| Goldbacher et al 2009 ⁴⁴ | DSM-IV MDD | HR (95% CI) depression as | Overall: 1.22 (0.75 to 2.92) | NR | |
| SWAN) N=429) | criteria using SCID-IV | a predictor of high fasting glucose; 7-year follow-up ^r | | | |
| Prospective cohort | | gracose, r year ronow-up | | | |
| Meta-Analyses | | | | | |
| Cosorove et al 2008 ²⁷ | Any assessment | Pooled BR (95% CI) risk of | Fixed/random effects model | NR | |

| Cosgrove et al 2008 ²⁷ 14 studies (N = NR) | Any assessment of MDD or raised depression score on a validated scale | Pooled RR (95% CI) risk of developing T2DM associated with depression | Fixed/random effects model Depression score or DIS for diagnosis: 1.33 (1.19 to 1.46)/1.17 (1.05 to 1.29) Depression scales for diagnosis: 1.42 (1.18 to 1.66)/1.25 (1.02 to 1.48) | NR |
|---|---|---|---|----|
| Mezuk et al 2008b ⁴⁵ 20 studies (N = NR) | NR | Pooled RR (95% CI) incident T2DM in people with depression | Overall: 1.60 (1.37 to 1.88) Age < 50 years: 1.96; <i>P</i> < .001 Age ≥ 50 years: 1.50; <i>P</i> < .001 Women: 1.26 (0.95 to 1.67) Men: 1.57 (1.24 to 1.99) | NR |
| Rotella and Mannucci 2013 ²⁹ 23 studies (N=424,557) | Any method included | Pooled HR (95% CI) incident diabetes in people with vs without depression | Overall: 1.379 (1.227 to 1.550); <i>P</i> < .001 Use of antidepressant: 1.68 (1.17 to 2.40); <i>P</i> = .005 Depression diagnosis, untreated: 1.56 (0.92 to 2.65); <i>P</i> = .09 | NR |
| Vancampfort et al 2015 ³⁰ 17 studies (N = 158,834) | Interview- defined MDD according to the DSM or <i>ICD</i> | Pooled RR (95% CI) risk of T2DM in people with MDD | 1.49 (1.29 to 1.72); <i>P</i> < .001 | NR |

^aWhen multiple levels of covariate adjustment were reported, the model with the greatest level of adjustment is reported here. Unless otherwise specified, the effect estimate is for the comparison of depression vs no depression. Statistically significant differences (P < .05) are shown in bold; P values are reported when available.

bFor the "Depression Recurrence/Severity" category, certain studies evaluated the association of certain subtypes of depression such as recurrent depression or certain severity levels depression on the risk or severity of comorbid disease.

^CAdjusted for age, sex, survey, lifestyle risk factors (smoking, alcohol consumption, physical inactivity), and metabolic risk factors (hypertension, dyslipidemia ^dAdjusted for age as a continuous and quadratic variable, sex, and number of physician visits (\geq 5).

^eAdjusted for age, sex, living situation, educational level, BMI, hypertension, statin use, current smoking, family history, functional disability, alcohol consumption, antidepressant treatment, and antipsychotic treatment.

^fAdjusted for age, BMI, family history of diabetes, smoking, physical activity, and socioeconomic position. Middle quartiles were combined into a single group ⁹Adjusted for age at baseline, sex, race, marital status, education level, BMI, cigarette smoking, functional limitations index, self-report of limited ability to

work, and household income.

Study 1: adjusted for sex, hypertension, CHD, cerebrovascular disease, and cancer; Study 2: adjusted for sex. Participants in Study 2 did not have a clear diagnosis of depression, only antidepressant medication use (treatment for > 6 months).

Adjusted for age, marriage status, living alone, hypertension, obesity, smoking, alcohol use, snoring, and sleep difficulty (difficulties initiating sleep; difficulties maintaining sleep) or sleep duration (\leq 5 h and \geq 9 h).

^kSignificant at a lower level of adjustment only. ^IAdjusted for age, sex, ethnicity, education, smoking status, alcohol use, antidepressant use, and social network size (1981–2005 analysis); additionally adjusted for BMI, family history of diabetes, stairs climbed per day, frequency of eating balanced meals or social network size, and frequency of social contact with relatives (1993–2005 analysis).

^mAdjusted for age, sex, and genetic risk.

Adjusted for age, sex, BMI, fasting glucose, SBP, triacylglycerol, HDL cholesterol, smoking, and the presence of the other conditions (CVD, heart failure, chronic kidney disease).

^oAdjusted for family history of diabetes, marital status, alcohol consumption, smoking status, physical activity level, coffee, whole grain, red/processed meat, and soft drinks.

^PAdjusted for baseline age, CVD, education, BMI, alcohol use, cigarette use, lifetime anxiety disorder, and stressful events. ^qAdjusted for age categories, marital status, education, employee status, smoking, physical inactivity, and risky alcohol consumption.

Adjusted for baseline age and race. Abbreviations: AGECAT = Automated Geriatric Examination for Computer Assisted Taxonomy; BMI = body mass index; CES-D = Center for Epidemiologic Studies-Depression; CHD = coronary heart disease; CID = Composite International Diagnostic Interview; CIDI-S = Composite International Diagnostic Interview–Short Form; CID-S = Composite International Diagnostic-Screener; CVD = cardiovascular disease; DEEX = DEpression and EXhaustion subscale; DIS = Diagnostic Interview Schedule; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; ECA = Epidemiologic Catchment Area; GMS = Geriatric Mental State; HDL = high-density lipoprotein; HR = hazard ratio; ICD = International Classification of Diseases; KORA = Cooperative Health Research in the Region of Augsburg; M-CIDI = Munich-Composite International Diagnostic Interview; MDD = major depressive disorder; MHI-5 = 5-item Mental Health Inventory; MONICA = Monitoring of Trends and Determinants in Cardiovascular Disease Augsburg; NR = not reported; NS = not significant; OR = odds ratio; RR = risk ratio; SALT = Screening Across the Lifespan Twin; SBP = systolic blood pressure; SCAN = Schedules for the Clinical Assessment of Neuropsychiatry; SCID-IV = Structured Clinical Interview for DSM-IV disorders; SHIP = Study of Health In Pomerania; SWAN = Study of Women's Health Across the Nation; T2DM = type 2 diabetes mellitus; ZARADEMP = Zaragoza Dementia and Depression.